KR20230022151A - 거대고리 화합물의 치료 용도 - Google Patents

거대고리 화합물의 치료 용도 Download PDF

Info

Publication number
KR20230022151A
KR20230022151A KR1020227034099A KR20227034099A KR20230022151A KR 20230022151 A KR20230022151 A KR 20230022151A KR 1020227034099 A KR1020227034099 A KR 1020227034099A KR 20227034099 A KR20227034099 A KR 20227034099A KR 20230022151 A KR20230022151 A KR 20230022151A
Authority
KR
South Korea
Prior art keywords
cancer
carcinoma
compound
met
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227034099A
Other languages
English (en)
Korean (ko)
Inventor
브리온 윌리엄 머레이
데이용 자이
징롱 제이. 쿠이
Original Assignee
터닝 포인트 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 터닝 포인트 테라퓨틱스, 인크. filed Critical 터닝 포인트 테라퓨틱스, 인크.
Publication of KR20230022151A publication Critical patent/KR20230022151A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
KR1020227034099A 2020-03-02 2021-03-01 거대고리 화합물의 치료 용도 Pending KR20230022151A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062984159P 2020-03-02 2020-03-02
US62/984,159 2020-03-02
PCT/US2021/020255 WO2021178296A1 (en) 2020-03-02 2021-03-01 Therapeutic uses of macrocyclic compounds

Publications (1)

Publication Number Publication Date
KR20230022151A true KR20230022151A (ko) 2023-02-14

Family

ID=77613771

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227034099A Pending KR20230022151A (ko) 2020-03-02 2021-03-01 거대고리 화합물의 치료 용도

Country Status (11)

Country Link
US (1) US20250262216A1 (https=)
EP (1) EP4114530A4 (https=)
JP (1) JP2023515687A (https=)
KR (1) KR20230022151A (https=)
CN (1) CN115397514A (https=)
AU (1) AU2021229457A1 (https=)
BR (1) BR112022017425A2 (https=)
CA (1) CA3174455A1 (https=)
IL (1) IL295938A (https=)
MX (1) MX2022010945A (https=)
WO (1) WO2021178296A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111902417B (zh) 2018-04-25 2023-07-28 北京普祺医药科技股份有限公司 一种二芳基巨环化合物、药物组合物以及其用途
US20240132517A1 (en) * 2021-02-10 2024-04-25 Goharmony Therapeutics (Shenzhen) Co., Ltd. Macrocyclic compound, pharmaceutical composition, and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
ES2933350T3 (es) * 2014-01-24 2023-02-06 Turning Point Therapeutics Inc Macrociclos de diarilo como moduladores de proteína quinasas
RU2765181C2 (ru) * 2015-07-06 2022-01-26 Тёрнинг Поинт Терапьютикс, Инк. Полиморфная форма диарильного макроцикла
US10689400B2 (en) * 2016-07-28 2020-06-23 Turning Point Therapeutics, Inc. Macrocycle kinase inhibitors
CN111182903A (zh) * 2017-07-28 2020-05-19 特普医药公司 巨环化合物及其用途
CN114423762B (zh) * 2019-09-30 2024-03-29 浙江海正药业股份有限公司 大环类衍生物及其制备方法和用途

Also Published As

Publication number Publication date
US20250262216A1 (en) 2025-08-21
AU2021229457A1 (en) 2022-10-20
IL295938A (en) 2022-10-01
CN115397514A (zh) 2022-11-25
BR112022017425A2 (pt) 2022-11-29
EP4114530A4 (en) 2024-04-17
MX2022010945A (es) 2022-10-07
CA3174455A1 (en) 2021-09-10
WO2021178296A1 (en) 2021-09-10
JP2023515687A (ja) 2023-04-13
EP4114530A1 (en) 2023-01-11

Similar Documents

Publication Publication Date Title
KR102772574B1 (ko) 키랄 디아릴 매크로사이클 및 이것의 용도
JP7193475B2 (ja) ジアリール大環状化合物を含む併用療法
Rizzolio et al. CDK inhibitors: from the bench to clinical trials
US20140088143A1 (en) Method of Inhibiting Constitutively Active Phosphorylated FLT3 Kinase
EP3585389A1 (en) Treatment of egfr-driven cancer with fewer side effects
AU2017417160A1 (en) Use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea and analogs for the treatment of cancers associated with genetic abnormalities in platelet derived growth factor receptor alpha
WO2019199883A1 (en) Treatment of cancers having driving oncogenic mutations
EP4065395A1 (en) Combination therapy involving diaryl macrocyclic compounds
JP2022551652A (ja) 線維芽細胞増殖因子受容体シグナル伝達の調節不全を伴う癌の標的処置
KR20240095536A (ko) 헤테로방향족 매크로사이클릭 에테르 화합물을 사용한 고형 종양의 치료 방법
US10835525B2 (en) Method of inhibiting mutant C-KIT
KR20230022151A (ko) 거대고리 화합물의 치료 용도
KR20240115884A (ko) Fgfr 키나제 억제제를 이용하는 암의 치료
US20230241052A1 (en) Method of inhibiting mutant c-kit
EP4034121A1 (en) Treatment of egfr mutant-related cancers using a combination of egfr and cdk4/6 inhibitors
CN101010082A (zh) 米哚妥林用于治疗胃肠道基质瘤的用途
CN121969398A (zh) 抗体偶联药物及其用途
JP2023530734A (ja) アイソフォーム特異的アルデヒドデヒドロゲナーゼ阻害剤
BR122024018560A2 (pt) Uso de 1-[4-bromo-5-[1-etil-7-(metilamino)-2-oxo-1,2-dihidro-1,6-naftiridin- 3-il]-2-fluorofenil]-3-fenilureia e análogos para o tratamento de cânceres associados a anormalidades genéticas no receptor alfa do fator de crescimento derivado de plaquetas

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902